Print Page  |  Close Window

Investors


Corporate Profile

Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

More »
DateTitle 
12/08/17Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be featured in an oral presentation at the 2017 American Society of Hematology Annual Meeting being held in Atlanta, GA from December 9 to December 12, 2017. During the presentation, James B. Bussel, M.D., professor eme... 
Printer Friendly Version
11/07/17Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 7, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2017. Recent Achievements On October 2, 2017, Rigel announced that the U.S. Food and Drug Administration (FDA) is not currently planning on holding an Oncology Drugs Advisory Committee (ODAC) meeting to discuss the New Drug Application (N... 
Printer Friendly Version
11/02/17Rigel Welcomes Gregg Lapointe to Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Gregg Lapointe, CPA, MBA has been appointed to Rigel's board of directors. Currently the chief executive officer (CEO) and co-founder of Cerium Pharmaceuticals, Inc., Mr. Lapointe offers Rigel's board nearly three decades of commercial and financial experience bringing products to market in the areas of medical devices and rare diseases.  "We look forward to working with M... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.68
Change (%) - 0.3 (7.54%)
Volume1,885,769
Data as of 12/11/17 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $3.68 with a 52 week high of $4.47 and a 52 week low of $1.94.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.